Valaciclovir and diclofenac combination therapy for functional somatic syndromes
The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valacyclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valacyclovir and diclofenac.
1. A method to treat a subject who is infected with herpes simplex virus type 1 and who is afflicted with one or more functional somatic syndrome conditions, the method comprising administering to the subject a therapeutically-effective combination of valacyclovir and diclofenac, wherein the amount of valacyclovir is administered in a total daily dose range from about 750 mg to about 2000 mg, and wherein the amount of diclofenac is administered in a total daily dose range from about 100 mg to about 150 mg, wherein the one or more functional somatic syndrome condition is selected from the group consisting of fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, chronic depression, chronic clinical anxiety disorder and chronic interstitial cystitis.
2. The method of claim 1 , wherein the condition is fibromyalgia.
3. The method of claim 1 , wherein the condition is chronic fatigue syndrome.
4. The method of claim 1 , wherein the condition is irritable bowel syndrome.
5. The method of claim 1 , wherein the condition is a combination of fibromyalgia, chronic fatigue syndrome and irritable bowel syndrome, coexistent in the subject.
6. The method of claim 1 , wherein the amount of valacyclovir is administered in a total daily dose range from about 750 mg to about 1250 mg.
7. The method of claim 1 , wherein the amount of valacyclovir administered in a total daily dose is about 750 mg, and wherein the amount of diclofenac administered in a total daily dose is about 100 mg or about 150 mg.